AUTHOR=Bulbul Ajaz , Husain Hatim TITLE=First-Line Treatment in EGFR Mutant Non-Small Cell Lung Cancer: Is There a Best Option? JOURNAL=Frontiers in Oncology VOLUME=8 YEAR=2018 URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2018.00094 DOI=10.3389/fonc.2018.00094 ISSN=2234-943X ABSTRACT=
First generation or second generation EGFR tyrosine kinase inhibitors are currently the standard of care for the first-line management of non-small cell lung cancer (NSCLC) patients with activating mutations within the kinase domain of the epidermal growth factor receptor gene (